GGrantIndex
← Leaderboards

Patrick J Pagano

Henry Ford Health System

$9,459,985
Attributed
$10,848,591
Total exposure
7
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,848,591 · 7

By mechanism

R01$8,284,825 · 4
T32$2,126,516 · 2
R21$437,250 · 1

Top collaborators

Others in their field

Top investigators on “Reactive Oxygen Species

Research focus

Reactive Oxygen SpeciesProductionMediatingBlood VesselsOxidantsIn VivoVascular DiseasesSignal TransductionPlayNadph OxidaseLeadCardiovascular DiseasesEndothelial CellsSuperoxidesHypertensionResistanceBaseRattusCellsAttenuatedInhibitor/AntagonistAlzheimer&AposResponseBlood Flow

Grant awards (35)

NOX2 Small Molecule Inhibitors as a Therapeutic Strategy in the Treatment of Alzheimer’s Disease$238,500
R21 · FY2025 · AG · contact PI
NOX2 Small Molecule Inhibitors as a Therapeutic Strategy in the Treatment of Alzheimer’s Disease$198,750
R21 · FY2024 · AG · contact PI
Progressive degenerative role of Nox and thrombospondin-1 in the aging vasculature$577,109
R01 · FY2022 · HL · contact PI
Predoctoral Training in Pharmacological Sciences (Resubmission)$312,217
T32 · FY2022 · GM · contact PI
Progressive degenerative role of Nox and thrombospondin-1 in the aging vasculature$577,109
R01 · FY2021 · HL · contact PI
Predoctoral Training in Pharmacological Sciences (Resubmission)$292,577
T32 · FY2021 · GM · contact PI
Progressive degenerative role of Nox and thrombospondin-1 in the aging vasculature$581,945
R01 · FY2020 · HL · contact PI
Predoctoral Training in Pharmacological Sciences (Resubmission)$192,822
T32 · FY2020 · GM · contact PI
Progressive degenerative role of Nox and thrombospondin-1 in the aging vasculature$581,804
R01 · FY2019 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$184,807
T32 · FY2019 · GM · contact PI
Reactive Oxygen Species in Vascular Disease$385,000
R01 · FY2018 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$188,520
T32 · FY2018 · GM · contact PI
Predoctoral Training in Pharmacological Sciences$75,223
T32 · FY2018 · GM · contact PI
Reactive Oxygen Species in Vascular Disease$385,000
R01 · FY2017 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$186,446
T32 · FY2017 · GM · contact PI
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction$500,500
R01 · FY2016 · HL · contact PI
Reactive Oxygen Species in Vascular Disease$385,000
R01 · FY2016 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$184,424
T32 · FY2016 · GM · contact PI
Reactive Oxygen Species in Vascular Disease$385,000
R01 · FY2015 · HL · contact PI
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction$379,225
R01 · FY2015 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$182,454
T32 · FY2015 · GM · contact PI
Augmentation of CD47 Signaling in Aging Exacerbates Cardiovascular Disease$115,500
R01 · FY2015 · HL · contact PI
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction$376,993
R01 · FY2014 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$148,408
T32 · FY2014 · GM · contact PI
TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction$362,950
R01 · FY2013 · HL · contact PI
Predoctoral Training in Pharmacological Sciences$178,618
T32 · FY2013 · GM · contact PI
Reactive Oxygen Species in Vascular Disease$373,226
R01 · FY2011 · HL · contact PI
Reactive Oxygen Species in Vascular Disease$373,226
R01 · FY2010 · HL · contact PI
Reactive Oxygen Species in Vascular Disease$373,226
R01 · FY2009 · HL · contact PI
Reactive Oxygen Species in Vascular Disease$362,000
R01 · FY2008 · HL · contact PI
Reactive Oxygen Species in Vascular Disease$352,012
R01 · FY2007 · HL · contact PI
Hypertension and Superoxide Generation$214,500
R01 · FY2005 · HL
Hypertension and Superoxide Generation$214,500
R01 · FY2004 · HL
Hypertension and Superoxide Generation$214,500
R01 · FY2003 · HL
Hypertension and Superoxide Generation$214,500
R01 · FY2002 · HL